Get started
Author

Robert N. Stuver

Observed names: R. Stuver, Robert N Stuver, Robert Stuver, Robert Stuver,, Stuver, Robert
ORCID: 0000-0003-0991-5170
Observed ORCID: 0000-0003-0991-5170
OpenAlex ID: A5086976880
Mycosis Fungoides and Sézary Syndrome
2023 · Robert Stuver,, Alison Moskowitz,, et al. · 172
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
2022 · Robert Stuver, Gunjan L. Shah, et al. · Cancer Cell · 86
Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry
2019 · Robert N. Stuver, Niloufer Khan, et al. · American Journal of Hematology · 44
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)
2024 · Alison J. Moskowitz, Robert N. Stuver, et al. · Blood · 42
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
2023 · William T. Johnson, Nivetha Ganesan, et al. · Blood Advances · 28
PDF
Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments
2023 · Robert Stuver, Shamir Geller · Frontiers in Immunology · 22
PDF
Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
2023 · Robert Stuver, Alison J. Moskowitz · Cancers · 22
PDF
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma
2024 · Pallawi Torka, Tatyana Feldman, et al. · Journal of Clinical Oncology · 21
PDF
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma
2023 · Robert Stuver, Steven M. Horwitz, et al. · British Journal of Haematology · 19
PDF
Cutaneous T‐cell lymphoma and dupilumab use: A retrospective matched cohort study of clinical characteristics and treatment outcomes
2024 · Robert Stuver, Stephen Dusza, et al. · Journal of the European Academy of Dermatology and Venereology · 17
PDF
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
2024 · Jessy Xinyi Han, Min Jung Koh, et al. · Blood Advances · 14
PDF
PD-1 Blockade before Autologous Stem Cell Transplantation Improves Outcomes in Relapsed/Refractory Classic Hodgkin Lymphoma: Results from a Multicenter Cohort
2023 · Sanjal H. Desai, Reid W. Merryman, et al. · Blood · 13
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis
2025 · Joseph M. Rocco, Joseph H. Oved, et al. · Blood · 12
Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
2024 · Alison Moskowitz, Gunjan L. Shah, et al. · Blood · 12
Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions
2023 · Robert Stuver, Steven M. Horwitz, et al. · Current Treatment Options in Oncology · 12
PDF
Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
2024 · Alison Moskowitz, Nivetha Ganesan, et al. · Blood · 11
PDF
Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2024 · Jacob D. Soumerai, Ahmet Dogan, et al. · Blood · 11
PDF
Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas
2023 · Robert Stuver, Zachary D. Epstein-Peterson, et al. · Haematologica · 10
PDF
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
2024 · William T. Johnson, Zachary D. Epstein-Peterson, et al. · Haematologica · 9
Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents
2023 · Ayo S Falade, Robert A. Redd, et al. · Blood · 9
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
2022 · Nazila Shafagati, Min J. Koh, et al. · Blood Advances · 9
PDF
Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma
2023 · Robert Stuver, Ariela Noy, et al. · British Journal of Haematology · 8
PDF
Retrospective characterization of nodal marginal zone lymphoma
2023 · Robert Stuver, Esther Drill, et al. · Blood Advances · 8
PDF
Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center
2025 · Viviane Liao, Leore Lavin, et al. · Journal of the American Academy of Dermatology · 7
Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
2024 · Lorenzo Falchi, Michelle Okwali, et al. · Blood · 7
Works count: 139
Citation count: 747
H-index: 12
I10-index: 18
Year
Topic
Type